Loading…
Korean biotech specializing in long-acting drug delivery (sustained-release peptide/protein formulations), including Parkinson's and diabetes candidates.
Korean biotech specializing in long-acting drug delivery (sustained-release peptide/protein formulations), including Parkinson's and diabetes candidates.
Moat: narrow (IP / patents). Proprietary long-acting microsphere depot technology applied across licensed drug candidates.
Headquarters: Daejeon, South Korea · Founded: 1997 · Employees: 163
Size Peptron (087010.KS) is a South Korea Health Care company (Biotechnology) with a market value of $1.67B, the 155th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩97,300 on 6 Nov 2026.
Performance Over six months the shares fell 62.6%, against -7.4% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 18 in its peer set.
Growth Revenue grew 15.9% over the last twelve months (peer median +23.4%); the operating margin is -427.5% (peer median -17.0%).
Valuation It trades at 369.5× enterprise value to sales against a peer median of 11.8× (2nd most expensive of 17).
Capital Return on invested capital runs 28.3 points below its cost of capital (6.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩6.00B | ₩5.63B | ₩3.15B | ₩3.34B | ₩5.81B |
| Revenue growth | — | +79% | -6% | -43% | — |
| Gross profit | -₩887M | ₩760M | -₩1.58B | -₩1.75B | -₩1.47B |
| EBITDA | -₩22.6B | -₩18.5B | -₩13.8B | -₩14.3B | -₩10.7B |
| Net income | -₩20.5B | -₩13.8B | -₩22.0B | -₩15.9B | -₩15.1B |
| Free cash flow | -₩29.5B | -₩23.1B | -₩13.8B | -₩11.7B | -₩13.2B |
| Capital expenditure | ₩9.58B | ₩3.00B | ₩2.16B | ₩869M | ₩1.72B |
| Total debt | ₩30.6B | ₩29.6B | ₩9.24B | ₩9.13B | ₩9.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Peptron 087010.KS | $1.67B | -63% | +16% | -427% | 369.5× | n/a |
| HanmiPharm 128940.KS | $4.36B | +2% | +14% | 16% | 3.5× | 5.0% |
| Alkermes Public ALKS | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 087010.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.5% | -8.8% | 4th lowest of 20 |
| 6-month return | -62.6% | -7.4% | lowest of 18 |
| Distance from 52-week high | -75.2% | -38.6% | 2nd lowest of 20 |
| Revenue growth (TTM) | +15.9% | +23.4% | 8th lowest of 19 |
| Operating margin | -427.5% | -17.0% | 7th lowest of 19 |
| EV / Sales | 369.5× | 11.8× | 2nd most expensive of 17 |
| ROIC minus cost of capital | -28.3 pp | -7.0 pp | 5th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | 3.3× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |